


## Baquiloprim-d<sub>6</sub>

<b>Cat. No.:</b>	HY-19581S
<b>CAS No.:</b>	1228182-50-0
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>14</sub> D <sub>6</sub> N <sub>6</sub>
<b>Molecular Weight:</b>	314.42
<b>Target:</b>	Bacterial; Antibiotic; Isotope-Labeled Compounds
<b>Pathway:</b>	Anti-infection; Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Baquiloprim-d <sub>6</sub> is deuterium labeled Baquiloprim. Baquiloprim, an antibiotic, is a selective inhibitor of bacterial dihydrofolate reductases. Baquiloprim possesses in vitro bacteriostatic activity against both Gram-negative and Gram-positive bacteria[1][2].
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Lewicki J, et, al. Oral bioavailability and pharmacokinetics of baquiloprim in dwarf goats. *Res Vet Sci.* 1995 May;58(3):268-71.
- [3]. White DG, et, al. Comparison of danofloxacin with baquiloprim/sulphadimidine for the treatment of experimentally induced *Escherichia coli* diarrhoea in calves. *Vet Rec.* 1998 Sep 5;143(10):273-6.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA